TP53 and acute myeloid leukemia: TP53 missense mutations result in a loss of protein function and exert a dominant negative effect in AML[21]; such mutations have also been associated with low responses to chemotherapy and poor prognoses.[22] However, patients with AML who harbor TP53 mutations have responded favorably to decitabine[23]; moreover, TP53 mutations are reportedly useful as a risk stratification parameter.[24] Therefore, the higher prevalence of TP53 mutations among South Korean patients with AML may have important therapeutic and prognostic implications.